Evernow, Inc.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Evernow, Inc. - overview
Established
2019
Location
San Francisco, CA, US
Primary Industry
Healthcare
About
Based in California, US, and founded in 2019 by its CEO Alicia Jackson, Evernow, Inc. operates as a telehealth company. In April 2022, Evernow, Inc. raised USD 28.
5 million in a series A funding led by new investor New Enterprise Associates, with participation from other new investors, including 8VC, Coelius Capital, and Refactor Capital. Evernow offers menopausal hormone therapy (MHT) treatments such as estradiol patches, estradiol pills, and paroxetine, an SSRI (selective serotonin reuptake inhibitor), which can be used to treat hot flashes and night sweats. The company also offers an online platform for women to contact doctors and obtain prescription medications. It provides 24/7 telephone support to its customers.
The company generates its revenue by charging a subscription of USD 129 per month. The company plans to use the April 2022 funding to expand its team, build a member community, and leverage the company's extensive data and research that will focus on product development.
Current Investors
New Enterprise Associates, 8VC, Refactor Capital
Primary Industry
Healthcare
Sub Industries
Healthcare, Systems Management Software
Website
www.evernow.com
Verticals
HealthTech
Company Stage
Series B
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.